{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:39:33Z","timestamp":1786786773626,"version":"build-2736575974"},"reference-count":92,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Blinatumomab and inotuzumab ozogamicin have demonstrated efficacy in treating relapsed\/refractory B-cell acute lymphoblastic leukemia (B-ALL) and improving outcomes compared with conventional chemotherapy. Encouraging results have been observed in both younger and older patients with Philadelphia chromosome (Ph)\u2013positive and Ph-negative B-ALL treated with these immunotherapy agents across several clinical trials. Treatment with inotuzumab ozogamicin and\/or blinatumomab leads to high rates of deep measurable residual disease negativity and may enhance survival compared with chemotherapy-only approaches, reducing the need for intensive chemotherapy, and potentially the need for allogeneic stem cell transplantation. Herein, we review the incorporation of blinatumomab and\/or inotuzumab ozogamicin into frontline B-ALL regimens, including the potential use of chemotherapy-free approaches in select patient subgroups. We also explore the potential role of CAR T-cell therapies in the frontline setting for high-risk patients, as well as novel strategies to further improve outcomes in patients with B-ALL.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7050","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T18:14:01Z","timestamp":1752516841000},"source":"Crossref","is-referenced-by-count":7,"title":["Incorporation of Immunotherapy Into Adult B-Cell Acute Lymphoblastic Leukemia Therapy"],"prefix":"10.6004","volume":"23","author":[{"given":"Fadi G.","family":"Haddad","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Am J Hematol","first-page":"650","article-title":"Acute lymphoblastic leukemia: a population\u2010based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980\u20132017","volume":"96","author":"Sasaki K","year":"2021","unstructured":"Sasaki K, Jabbour E, Short NJ,  Acute lymphoblastic leukemia: a population\u2010based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980\u20132017. Am J Hematol 2021;96:650\u2013658."},{"key":"B2","series-title":"J Hematol Oncol","first-page":"22.","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour E","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N,  The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol 2023;16:22."},{"key":"B3","series-title":"J Clin Oncol","first-page":"547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian HM","year":"2000","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL,  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547\u2013561."},{"key":"B4","series-title":"N Engl J Med","first-page":"836","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N,  Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376:836\u2013847."},{"key":"B5","series-title":"N Engl J Med","first-page":"740","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian HM","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M,  Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740\u2013753."},{"key":"B6","series-title":"Leuk Lymphoma","first-page":"1405","article-title":"Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens","volume":"65","author":"Short NJ","year":"2024","unstructured":"Short NJ, Kantarjian H, Jabbour E. Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens. Leuk Lymphoma 2024;65:1405\u20131417."},{"key":"B7","series-title":"Blood Cancer J","first-page":"81","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden","volume":"10","author":"DeAngelo DJ","year":"2020","unstructured":"DeAngelo DJ, Advani AS, Marks DI,  Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J 2020;10:81."},{"key":"B8","series-title":"Curr Treat Options Oncol","first-page":"993","article-title":"Treatment of relapsed acute lymphocytic leukemia in adult patients","volume":"25","author":"Molina JC","year":"2024","unstructured":"Molina JC, Carraway HE. Treatment of relapsed acute lymphocytic leukemia in adult patients. Curr Treat Options Oncol 2024;25:993\u20131010."},{"key":"B9","series-title":"Haematologica","first-page":"2072","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Cabannes-Hamy A","year":"2022","unstructured":"Cabannes-Hamy A, Brissot E, Leguay T,  High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. Haematologica 2022;107:2072\u20132080."},{"key":"B10","series-title":"J Hematol Oncol","article-title":"Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia","volume":"16","author":"Kantarjian H","year":"2023","unstructured":"Kantarjian H, Haddad FG, Jain N,  Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol 2023;16:44."},{"key":"B11","series-title":"Lancet Oncol","first-page":"240","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian H","year":"2018","unstructured":"Kantarjian H, Ravandi F, Short NJ,  Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2018;19:240\u2013248."},{"key":"B12","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"e168","article-title":"Dose-dense mini-hyper-CVD, inotuzumab ozogamicin and blinatumomab achieves rapid MRD-negativity in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"24","author":"Short NJ","year":"2024","unstructured":"Short NJ, Jabbour E, Jamison T,  Dose-dense mini-hyper-CVD, inotuzumab ozogamicin and blinatumomab achieves rapid MRD-negativity in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2024;24:e168\u2013173."},{"key":"B13","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"S284","article-title":"ALL-808 very promising results of the dose dense (D-D) mini-hyper-CVD-inotuzumab-blinatumomab phase 2 trial in patients with relapsed-refractory acute lymphoblastic leukemia","volume":"24","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Short N, Jain N,  ALL-808 very promising results of the dose dense (D-D) mini-hyper-CVD-inotuzumab-blinatumomab phase 2 trial in patients with relapsed-refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2024;24:S284\u2013285."},{"key":"B14","series-title":"Blood","first-page":"284","article-title":"Outcome with the hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph) positive acute lymphocytic leukemia (ALL)","volume":"108","author":"Thomas DA","year":"2006","unstructured":"Thomas DA, Kantarjian HM, Cortes J,  Outcome with the hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 2006;108:Abstract 284."},{"key":"B15","series-title":"Haematologica","first-page":"653","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver N","year":"2015","unstructured":"Daver N, Thomas D, Ravandi F,  Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2015;100:653\u2013661."},{"key":"B16","series-title":"Blood","first-page":"2070","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome\u2013positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi F","year":"2010","unstructured":"Ravandi F, O\u2019Brien S, Thomas D,  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome\u2013positive (Ph+) acute lymphoblastic leukemia. Blood 2010;116:2070\u20132077."},{"key":"B17","series-title":"Blood Adv","first-page":"250","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi F","year":"2016","unstructured":"Ravandi F, Othus M, O\u2019Brien SM,  US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv 2016;1:250\u2013259."},{"key":"B18","series-title":"Lancet Oncol","first-page":"1547","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour E","year":"2015","unstructured":"Jabbour E, Kantarjian H, Ravandi F,  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 2015;16:1547\u20131555."},{"key":"B19","series-title":"Am J Hematol","first-page":"493","article-title":"Frontline combination of ponatinib and hyper\u2010CVAD in Philadelphia chromosome\u2010positive acute lymphoblastic leukemia: 80\u2010months follow\u2010up results","volume":"98","author":"Kantarjian H","year":"2023","unstructured":"Kantarjian H, Short NJ, Jain N,  Frontline combination of ponatinib and hyper\u2010CVAD in Philadelphia chromosome\u2010positive acute lymphoblastic leukemia: 80\u2010months follow\u2010up results. Am J Hematol 2023;98:493\u2013501."},{"key":"B20","series-title":"N Engl J Med","first-page":"1613","article-title":"Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0 R","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A,  Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med 2020;383:1613\u20131623."},{"key":"B21","series-title":"Lancet Haematol","first-page":"e24","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour E","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N,  Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 2023;10:e24\u201334."},{"key":"B22","series-title":"N Engl J Med","first-page":"439","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude SL","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J,  Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439\u2013448."},{"key":"B23","series-title":"Lancet","first-page":"491","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah BD","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO,  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021;398:491\u2013502."},{"key":"B24","series-title":"Lancet Haematol","first-page":"e878","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour E","year":"2022","unstructured":"Jabbour E, Short NJ, Jain N,  Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol 2022;9:e878\u2013885."},{"key":"B25","series-title":"J Clin Oncol","first-page":"e19017","article-title":"A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)\u2013negative B-cell acute lymphoblastic leukemia (ALL)","volume":"41","author":"Short NJ","year":"2023","unstructured":"Short NJ, Jabbour E, Jain N,  A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)\u2013negative B-cell acute lymphoblastic leukemia (ALL). J Clin Oncol 2023;41(16 Suppl):Abstract e19017."},{"key":"B26","series-title":"Blood","first-page":"1500","article-title":"Impact of high-risk cytogenetics (HR-CTG) on the outcome of newly diagnosed adult patients with Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) treated with frontline blinatumomab (Blina) and\/or inotuzumab ozogamicin (Ino) Containing hyperCVAD (HCVAD) therapy","volume":"142","author":"Senapati J","year":"2023","unstructured":"Senapati J, Jabbour E, Short NJ,  Impact of high-risk cytogenetics (HR-CTG) on the outcome of newly diagnosed adult patients with Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) treated with frontline blinatumomab (Blina) and\/or inotuzumab ozogamicin (Ino) Containing hyperCVAD (HCVAD) therapy. Blood 2023; 142(Suppl):Abstract 1500."},{"key":"B27","series-title":"Lancet Haematol","first-page":"e523","article-title":"Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial","volume":"7","author":"Jabbour E","year":"2020","unstructured":"Jabbour E, Richard-Carpentier G, Sasaki Y,  Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 2020;7:e523\u2013533."},{"key":"B28","series-title":"Blood","first-page":"826","article-title":"Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult Ph\u2013 B-lineage acute lymphoblastic leukemia. Final results of the phase II Gimema LAL2317 trial","volume":"142","author":"Chiaretti S","year":"2023","unstructured":"Chiaretti S, Della Starza I, Santoro A,  Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult Ph\u2013 B-lineage acute lymphoblastic leukemia. Final results of the phase II Gimema LAL2317 trial. Blood 2023;142(Suppl 1):Abstract 826."},{"key":"B29","series-title":"HemaSphere","first-page":"266","article-title":"P366: Blinatumomab added to prephase and consolidation therapy in newly diagnosed precursor B-ALL in adults. A phase II HOVON trial","volume":"6","author":"Rijneveld A","year":"2022","unstructured":"Rijneveld A, Gradowska P, Bellido M,  P366: Blinatumomab added to prephase and consolidation therapy in newly diagnosed precursor B-ALL in adults. A phase II HOVON trial. HemaSphere 2022;6:266\u2013267."},{"key":"B30","series-title":"Blood","first-page":"507","article-title":"Blinatumomab during consolidation in high-risk Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) adult patients: a two-cohort comparison within the GRAALL-2014\/B study","volume":"140","author":"Boissel N","year":"2022","unstructured":"Boissel N, Huguet F, Leguay T,  Blinatumomab during consolidation in high-risk Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) adult patients: a two-cohort comparison within the GRAALL-2014\/B study. Blood 2022;140:507\u2013509."},{"key":"B31","series-title":"HemaSphere","first-page":"e811479d","article-title":"P365: Sequential blinatumomab with reduced intensity chemotherapy for older adults with newly diagnosed Ph-B-precursor acute lymphoblastic leukemia \u2013 final results of the ALLG ALL08 study","volume":"7","author":"Fleming S","year":"2023","unstructured":"Fleming S, Reynolds J, Bajel A,  P365: Sequential blinatumomab with reduced intensity chemotherapy for older adults with newly diagnosed Ph-B-precursor acute lymphoblastic leukemia \u2013 final results of the ALLG ALL08 study. HemaSphere 2023;7:e811479d."},{"key":"B32","series-title":"N Engl J Med","first-page":"320","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow MR","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ,  Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med 2024;391:320\u2013333."},{"key":"B33","series-title":"Blood","first-page":"2877","article-title":"Assessment of outcomes of consolidation therapy by number of cycles of blinatumomab received in newly diagnosed measurable residual disease negative patients with B-lineage acute lymphoblastic leukemia: in the ECOG-ACRIN E1910 randomized phase III National Clinical Trials Network trial","volume":"142","author":"Luger SM","year":"2023","unstructured":"Luger SM, Sun Z, Mattison RJ,  Assessment of outcomes of consolidation therapy by number of cycles of blinatumomab received in newly diagnosed measurable residual disease negative patients with B-lineage acute lymphoblastic leukemia: in the ECOG-ACRIN E1910 randomized phase III National Clinical Trials Network trial. Blood 2023;142(Suppl 1):Abstract 2877."},{"key":"B34","article-title":"FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","author":"US Food and Drug Administration","unstructured":"US Food and Drug Administration. FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Accessed April 15, 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell"},{"key":"B35","series-title":"Blood","first-page":"308","article-title":"Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial","volume":"144","author":"DeAngelo DJ","year":"2024","unstructured":"DeAngelo DJ, Yin J, Advani AS,  Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial. Blood 2024;144(Suppl 1):Abstract 308."},{"key":"B36","series-title":"Blood","first-page":"1878","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer MB","year":"2017","unstructured":"Geyer MB, Hsu M, Devlin SM,  Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood 2017;129:1878\u20131881."},{"key":"B37","series-title":"Blood","first-page":"3981","article-title":"Patient characteristics and treatment patterns in elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) using 100% Medicare ALL data","volume":"128","author":"Li S","year":"2016","unstructured":"Li S, Molony JT, Chia V, Katz AJ. Patient characteristics and treatment patterns in elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) using 100% Medicare ALL data. Blood 2016; 128(Suppl):Abstract 3981."},{"key":"B38","series-title":"Blood","first-page":"1493","article-title":"Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL)","volume":"120","author":"Goekbuget N","year":"2012","unstructured":"Goekbuget N, Beck J, Brueggemann M,  Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL). Blood 2012;120(Suppl):1493."},{"key":"B39","series-title":"Cancer","first-page":"2097","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O\u2019Brien S","year":"2008","unstructured":"O\u2019Brien S, Thomas DA, Ravandi F,  Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 2008;113:2097\u20132101."},{"key":"B40","series-title":"Lancet Haematol","first-page":"e433","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour E","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J,  Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 2023;10:e433\u2013444."},{"key":"B41","series-title":"Cancer","first-page":"2579","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis","volume":"125","author":"Jabbour EJ","year":"2019","unstructured":"Jabbour EJ, Sasaki K, Ravandi F,  Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis. Cancer 2019;125:2579\u20132586."},{"key":"B42","series-title":"J Clin Oncol","first-page":"7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703","volume":"41","author":"Wieduwilt MJ","year":"2023","unstructured":"Wieduwilt MJ, Yin J, Kour O,  Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703. J Clin Oncol 2023;41(Suppl):Abstract 7006."},{"key":"B43","series-title":"J Clin Oncol","first-page":"1574","article-title":"SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome\u2013negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani AS","year":"2022","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM,  SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome\u2013negative B-cell acute lymphoblastic leukemia. J Clin Oncol 2022;40:1574\u20131582."},{"key":"B44","series-title":"Blood","first-page":"964","article-title":"Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph\/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL Bold trial","volume":"142","author":"Goekbuget N","year":"2023","unstructured":"Goekbuget N, Schwartz S, Faul C,  Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph\/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL Bold trial. Blood 2023;142(Suppl 1):Abstract 964."},{"key":"B45","series-title":"J Clin Oncol","first-page":"273","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome\u2013negative B-precursor ALL","volume":"42","author":"Stelljes M","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N,  Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome\u2013negative B-precursor ALL. J Clin Oncol 2024;42:273\u2013282."},{"key":"B46","series-title":"Blood","first-page":"511","article-title":"Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy provides very good outcome in older patients with newly diagnosed CD22+ Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: first results from the EWALL-INO study","volume":"138","author":"Chevallier P","year":"2021","unstructured":"Chevallier P, Leguay T, Doubek M,  Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy provides very good outcome in older patients with newly diagnosed CD22+ Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: first results from the EWALL-INO study. Blood 2021;138(Suppl 1):Abstract 511."},{"key":"B47","series-title":"Blood","first-page":"6134","article-title":"Blinatumomab alternating with low-intensity chemotherapy (CT) treatment for older adults with newly diagnosed Philadelphia (Ph)-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is well tolerated and efficacious: safety run-in results for the phase 3 randomized controlled Golden Gate Study","volume":"140","author":"Jabbour E","year":"2022","unstructured":"Jabbour E, Aldoss I, Fleming S,  Blinatumomab alternating with low-intensity chemotherapy (CT) treatment for older adults with newly diagnosed Philadelphia (Ph)-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is well tolerated and efficacious: safety run-in results for the phase 3 randomized controlled Golden Gate Study. Blood 2022;140(Suppl 1):6134\u20136136."},{"key":"B48","series-title":"N Engl J Med","first-page":"875","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta S","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA,  Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med 2025;392:875\u2013891."},{"key":"B49","series-title":"J Clin Oncol","first-page":"2246","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters R","year":"2019","unstructured":"Pieters R, De Lorenzo P, Ancliffe P,  Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study. J Clin Oncol 2019;37:2246\u20132256."},{"key":"B50","series-title":"N Engl J Med","first-page":"1572","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis IM","year":"2023","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS,  Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med 2023;388:1572\u20131581."},{"key":"B51","series-title":"Blood","first-page":"2816","article-title":"Blinatumomab with de-escalated chemotherapy for infant KMT2A-rearranged B-cell acute lymphoblastic leukemia","volume":"144","author":"Hodder A","year":"2024","unstructured":"Hodder A, Mishra AK, Connor P,  Blinatumomab with de-escalated chemotherapy for infant KMT2A-rearranged B-cell acute lymphoblastic leukemia. Blood 2024;144(Suppl 1):Abstract 2816."},{"key":"B52","series-title":"Blood","first-page":"2357","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret H","year":"2002","unstructured":"Dombret H, Gabert J, Boiron JM,  Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357\u20132366."},{"key":"B53","series-title":"Hematol Cell Ther","first-page":"119","article-title":"Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome","volume":"40","author":"Thomas X","year":"1998","unstructured":"Thomas X, Thiebaut A, Olteanu N,  Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther 1998;40:119\u2013128."},{"key":"B54","series-title":"Blood","first-page":"3353","article-title":"Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"85","author":"Chao NJ","year":"1995","unstructured":"Chao NJ, Blume KG, Forman SJ, Snyder DS. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995;85:3353\u20133354."},{"key":"B55","series-title":"Cancer","first-page":"4158","article-title":"Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Ravandi F","year":"2015","unstructured":"Ravandi F, O\u2019Brien SM, Cortes JE,  Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2015;121:4158\u20134164."},{"key":"B56","series-title":"Blood","first-page":"774","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome\u2013positive ALL","volume":"128","author":"Rousselot P","year":"2016","unstructured":"Rousselot P, Coud\u00e9 MM, Gokbuget N,  Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome\u2013positive ALL. Blood 2016;128:774\u2013782."},{"key":"B57","series-title":"JAMA Oncol","first-page":"1340","article-title":"Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013from intensive chemotherapy combinations to chemotherapy-free regimens","volume":"8","author":"Jabbour E","year":"2022","unstructured":"Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013from intensive chemotherapy combinations to chemotherapy-free regimens. JAMA Oncol 2022;8:1340\u20131348."},{"key":"B58","series-title":"Lancet Haematol","first-page":"e618","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour E","year":"2018","unstructured":"Jabbour E, Short NJ, Ravandi F,  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 2018;5:e618\u2013627."},{"key":"B59","series-title":"Blood","first-page":"3810","article-title":"12 versus 8 prophylactic intrathecal (IT) chemotherapy administration decrease incidence of central nervous system (CNS) relapse in patients (pts) with newly diagnosed Philadelphia (Ph)-positive acute lymphocytic leukemia (ALL)","volume":"134","author":"Paul S","year":"2019","unstructured":"Paul S, Sasaki K, Savoy JM,  12 versus 8 prophylactic intrathecal (IT) chemotherapy administration decrease incidence of central nervous system (CNS) relapse in patients (pts) with newly diagnosed Philadelphia (Ph)-positive acute lymphocytic leukemia (ALL). Blood 2019;134(Suppl 1):3810."},{"key":"B60","series-title":"Am J Hematol","first-page":"E11","article-title":"Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"98","author":"Paul S","year":"2023","unstructured":"Paul S, Kantarjian H, Sasaki K,  Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol 2023;98:E11\u201314."},{"key":"B61","series-title":"Cancer","first-page":"3650","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis","volume":"122","author":"Sasaki K","year":"2016","unstructured":"Sasaki K, Jabbour EJ, Ravandi F,  Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer 2016;122:3650\u20133656."},{"key":"B62","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"257","article-title":"Efficacy of ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"18","author":"Jabbour E","year":"2018","unstructured":"Jabbour E, DerSarkissian M, Duh MS,  Efficacy of ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2018;18:257\u2013265."},{"key":"B63","series-title":"Blood","first-page":"504","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"128","author":"Short NJ","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K,  Impact of complete molecular response on survival in patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. Blood 2016;128:504\u2013507."},{"key":"B64","series-title":"Cancer","first-page":"2648","article-title":"Prognostic factors for progression in patients with Philadelphia chromosome\u2010positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors","volume":"127","author":"Sasaki K","year":"2021","unstructured":"Sasaki K, Kantarjian HM, Short NJ,  Prognostic factors for progression in patients with Philadelphia chromosome\u2010positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 2021;127:2648\u20132656."},{"key":"B65","series-title":"JAMA","first-page":"1814.","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"331","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I,  Ponatinib vs imatinib in frontline Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. JAMA 2024;331:1814."},{"key":"B66","series-title":"Cancer","first-page":"304","article-title":"Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B\u2010precursor acute lymphoblastic leukemia","volume":"126","author":"Rambaldi A","year":"2020","unstructured":"Rambaldi A, Ribera JM, Kantarjian HM,  Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B\u2010precursor acute lymphoblastic leukemia. Cancer 2020;126:304\u2013310."},{"key":"B67","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"897","article-title":"Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia","volume":"17","author":"Assi R","year":"2017","unstructured":"Assi R, Kantarjian H, Short NJ,  Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk 2017;17:897\u2013901."},{"key":"B68","series-title":"J Clin Oncol","first-page":"881","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Foa R","year":"2024","unstructured":"Foa R, Bassan R, Elia L,  Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol 2024;42:881\u2013885."},{"key":"B69","series-title":"Blood Adv","first-page":"1279","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani AS","year":"2023","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM,  Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Adv 2023;7:1279\u20131285."},{"key":"B70","series-title":"J Clin Oncol","first-page":"4246","article-title":"Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian H","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG,  Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol 2024;42:4246\u20134251."},{"key":"B71","series-title":"Blood","first-page":"835","article-title":"Efficacy and toxicity of frontline ponatinib plus blinatumomab for adult Ph+ ALL patients of all ages. Intermediate analysis of the GIMEMA ALL2820","volume":"144","author":"Chiaretti S","year":"2024","unstructured":"Chiaretti S, Leoncin M, Elia L,  Efficacy and toxicity of frontline ponatinib plus blinatumomab for adult Ph+ ALL patients of all ages. Intermediate analysis of the GIMEMA ALL2820. Blood 2024;144(Suppl 1):Abstract 835."},{"key":"B72","series-title":"JAMA Oncol","first-page":"e170580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia","volume":"3","author":"Berry DA","year":"2017","unstructured":"Berry DA, Zhou S, Higley H,  Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia. JAMA Oncol 2017;3:e170580."},{"key":"B73","series-title":"Am J Hematol","first-page":"257","article-title":"Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts","volume":"94","author":"Short NJ","year":"2019","unstructured":"Short NJ, Jabbour E, Albitar M,  Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts. Am J Hematol 2019;94:257\u2013265."},{"key":"B74","series-title":"Blood","first-page":"1522","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Bargou RC","year":"2018","unstructured":"Bargou RC, Nagorsen D, Zugmaier G,  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018;131:1522\u20131531."},{"key":"B75","series-title":"Blood","first-page":"554","article-title":"Blinatumomab for minimal residual disease (MRD) in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL): median overall survival (OS) is not reached in complete MRD responders at a median follow-up of 53.1 months","volume":"132","author":"Goekbuget N","year":"2018","unstructured":"Goekbuget N, Dombret H, Zugmaier G,  Blinatumomab for minimal residual disease (MRD) in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL): median overall survival (OS) is not reached in complete MRD responders at a median follow-up of 53.1 months. Blood 2018;132(Suppl 1):554."},{"key":"B76","series-title":"Am J Hematol","first-page":"1135","article-title":"Blinatumomab is associated with favorable outcomes in patients with B\u2010cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10\u2009\u2212\u20094 and higher","volume":"97","author":"Jabbour EJ","year":"2022","unstructured":"Jabbour EJ, Short NJ, Jain N,  Blinatumomab is associated with favorable outcomes in patients with B\u2010cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10\u2009\u2212\u20094 and higher. Am J Hematol 2022;97:1135\u20131141."},{"key":"B77","series-title":"Blood","first-page":"417","article-title":"Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission","volume":"143","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Haddad FG, Short NJ,  Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 2024;143:417\u2013421."},{"key":"B78","series-title":"Blood","first-page":"6119","article-title":"Gimema ALL2418: interim analysis of a phase IIa study of feasibility and effectiveness of inotuzumab ozogamicin in adult patients with B-cell acute lymphoblastic leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation","volume":"140","author":"Marconi G","year":"2022","unstructured":"Marconi G, Piciocchi A, Chiaretti S,  Gimema ALL2418: interim analysis of a phase IIa study of feasibility and effectiveness of inotuzumab ozogamicin in adult patients with B-cell acute lymphoblastic leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation. Blood 2022;140(Suppl 1):6119\u20136121."},{"key":"B79","series-title":"J Clin Oncol","first-page":"6504","article-title":"Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL): overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib\/II study","volume":"42","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Tholouli E, Sandhu KS,  Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL): overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib\/II study. J Clin Oncol 2024;42(Suppl):Abstract 6504."},{"key":"B80","series-title":"J Clin Oncol","first-page":"945","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz LM","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S,  Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol 2022;40:945\u2013955."},{"key":"B81","article-title":"Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia with marrow blasts <5%, including patients (pts) with NGS MRD negative disease","author":"Jain N","unstructured":"Jain N, Jabbour E, Short N,  Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia with marrow blasts <5%, including patients (pts) with NGS MRD negative disease. Presented at EHA 2024; June 13\u201316, 2024; Madrid, Spain. Abstract P413."},{"key":"B82","series-title":"Clin Cancer Res","first-page":"742","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss I","year":"2023","unstructured":"Aldoss I, Khaled SK, Wang X,  Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL. Clin Cancer Res 2023;29:742\u2013753."},{"key":"B83","series-title":"Blood","first-page":"966","article-title":"CD19-CAR T cells as definitive consolidation for older adults with B-cell acute lymphoblastic leukemia in first complete remission: a pilot study","volume":"144","author":"Aldoss I","year":"2024","unstructured":"Aldoss I, Wang X, Zhang J,  CD19-CAR T cells as definitive consolidation for older adults with B-cell acute lymphoblastic leukemia in first complete remission: a pilot study. Blood 2024;144(Suppl 1):Abstract 966."},{"key":"B84","series-title":"Blood","first-page":"891","article-title":"Dasatinib and CAR-T cell therapy for newly diagnosed Ph-positive acute lymphoblastic leukemia in adults","volume":"142","author":"Zhang M","year":"2023","unstructured":"Zhang M, Hu Y, Wei G,  Dasatinib and CAR-T cell therapy for newly diagnosed Ph-positive acute lymphoblastic leukemia in adults. Blood 2023;142(Suppl 1):Abstract 891."},{"key":"B85","series-title":"Am J Hematol","first-page":"1196","article-title":"Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT\u2010PCR for BCR::ABL1","volume":"98","author":"Short NJ","year":"2023","unstructured":"Short NJ, Jabbour E, Macaron W,  Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT\u2010PCR for BCR::ABL1. Am J Hematol 2023;98:1196\u20131203."},{"key":"B86","series-title":"Blood Adv","first-page":"4006","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short NJ","year":"2022","unstructured":"Short NJ, Kantarjian H, Ravandi F,  High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 2022;6:4006\u20134014."},{"key":"B87","series-title":"Am J Hematol","first-page":"E201","article-title":"Dismal outcomes of patients with relapsed\/refractory Philadelphia chromosome\u2010negative B\u2010cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab","volume":"97","author":"Short NJ","year":"2022","unstructured":"Short NJ, Macaron W, Konopleva M,  Dismal outcomes of patients with relapsed\/refractory Philadelphia chromosome\u2010negative B\u2010cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 2022;97:E201\u2013204."},{"key":"B88","series-title":"Leukemia","first-page":"2854","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan J","year":"2019","unstructured":"Pan J, Niu Q, Deng B,  CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 2019;33:2854\u20132866."},{"key":"B89","series-title":"Cancer Discov","first-page":"1440","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat VA","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E,  Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 2021;11:1440\u20131453."},{"key":"B90","series-title":"Blood Adv","first-page":"909","article-title":"A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"8","author":"Short NJ","year":"2024","unstructured":"Short NJ, Jabbour E, Jain N,  A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia. Blood Adv 2024;8:909\u2013915."},{"key":"B91","series-title":"Am J Hematol","first-page":"586","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Zugmaier G, Agrawal V,  Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol 2024;99:586\u2013595."},{"key":"B92","series-title":"Nature","first-page":"920","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa GC","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J,  The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 2023;615:920\u2013924."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/8\/article-e257050.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/8\/article-e257050.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/8\/article-e257050.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:36:55Z","timestamp":1754397415000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/8\/article-e257050.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":92,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7050","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}